References
- King CH , DickmanK, TischDJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet365 (9470), 1561–1569 (2005).
- Gouveia MJ , SantosJ, BrindleyPJet al. Estrogen-like metabolites and DNA-adducts in urogenital schistosomiasis-associated bladder cancer. Cancer Lett.359 (2), S0304–S3835 (2015).
- Gryseels B , PolmanK, ClerinxJ, KestensL. Human schistosomiasis. Lancet368 (9541), 1106–1118 (2006).
- King CH . Parasites and poverty: the case of schistosomiasis. Acta Trop.113 (2), 95–104 (2010).
- Redman CA , RobertsonA, FallonPGet al. Praziquantel: an urgent and exciting challenge. Parasitol. Today12 (1), 14–20 (1996).
- Sabah AA , FletcherC, WebbeG, DoenhoffMJ. Schistosoma mansoni: chemotherapy of infections of different ages. Exp. Parasitol.61 (3), 294–303 (1986).
- Bennett JL , DayT, LiangFT, IsmailM, FarghalyA. The development of resistance to anthelmintics: a perspective with an emphasis on the antischistosomal drug praziquantel. Exp. Parasitol.87 (3), 260–267 (1997).
- Coeli R , BabaEH, AraujoN, CoelhoPM, OliveiraG. Praziquantel treatment decreases Schistosoma mansoni genetic diversity in experimental infections. PLoS Negl. Trop. Dis.7 (12), e2596 (2013).
- Valentim CL , CioliD, ChevalierFDet al. Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites. Science342 (6164), 1385–1389 (2013).
- Chevalier FD , ValentimCL, LoVerdePT, AndersonTJ. Efficient linkage mapping using exome capture and extreme QTL in schistosome parasites. BMC Genomics15, 617 (2014).
- Gaba S , JamalS, ScariaV. Open Source Drug Discovery Consortium. Cheminformatics models for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase. Scientific World J.2014, 957107 (2014).
- Crowther GJ , ShanmugamD, CarmonaSJet al. Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl. Trop. Dis.4 (8), e804 (2010).
- Berriman M , HaasBJ, LoVerdePTet al. The genome of the blood fluke Schistosoma mansoni. Nature460 (7253), 352–358 (2009).
- Pierce RJ , Dubois-AbdesselemF, LancelotJ, AndradeL, OliveiraG. Targeting schistosome histone modifying enzymes for drug development. Curr. Pharm. Des.18 (24), 3567–3578 (2012).
- Anti-parasitic drug discovery in epigenetics. http://a-paraddise.cebio.org/
- Marek M , KannanS, HauserATet al. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog.9 (9), e1003645 (2013).
- Lancelot J , CabyS, Dubois-AbdesselemFet al. Schistosoma mansoni Sirtuins: characterization and potential as chemotherapeutic targets. PLoS Negl. Trop Dis.7 (9), e2428 (2013).
- Cabezas-Cruz A , LancelotJ, CabyS, OliveiraG, PierceRJ. Epigenetic control of gene function in schistosomes: a source of therapeutic targets?Front Genet.5, 317 (2014).